⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14015872 | 1.00 | — | — | |
| SCHEMBL9202546 | 1.00 | — | — | |
| SCHEMBL1726520 | 0.74 | — | — | |
| SCHEMBL24197897 | 0.73 | — | — | |
| SCHEMBL27123640 | 0.73 | — | — | |
| SCHEMBL8519756 | 0.69 | — | — | |
| SCHEMBL26427112 | 0.69 | — | — | |
| SCHEMBL7662726 | 0.69 | — | — | |
| SCHEMBL24278668 | 0.69 | — | — | |
| SCHEMBL10315764 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781574-B1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| CN-112867722-B | MACROCYCLIC SPIROETHERS (MACROCYCLIC SPIROETHERS) as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
| CN-112867722-A | MACROCYCLIC SPIROETHERS (MACROCYCLIC SPIROETHERS) as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3781574-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020147802-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130116169-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110201642-A1 | Bioactive Compounds | BLUNT JOHN | 2011-08-18 | — | — | US | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |